Amikacin (BAY416651): Mechanism, Resistance, and Benchmarks in Antibiotic Research

Executive Summary: Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A, characterized by a molecular weight of 585.6 and a chemical formula of C₂₂H₄₃N₅O₁₃ [APExBIO]. Its primary mechanism involves binding to bacterial 30S ribosomal subunits, thereby inhibiting protein synthesis and exerting bactericidal effects [Related Source]. Amikacin is notably resistant to most aminoglycoside-modifying enzymes, except for acetylation by AAC (6')-I, which confers resistance in some strains [Chen et al., 2025]. It is especially recommended for research on carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae. Amikacin demonstrates high solubility in water (≥5.86 mg/mL) and should be stored at -20°C for optimal stability [APExBIO].

Biological Rationale

Antibiotic resistance in Gram-negative bacteria, such as Enterobacter cloacae and Klebsiella pneumoniae, is a major clinical challenge, largely driven by the horizontal transfer of carbapenemase-encoding genes (CEGs) [Chen et al., 2025]. Amikacin (BAY416651) was developed as a semi-synthetic aminoglycoside to combat resistance mechanisms that render earlier agents ineffective. Unlike gentamicin and tobramycin, Amikacin retains activity against strains expressing several aminoglycoside-modifying enzymes, expanding its utility in resistance research. The ability to withstand enzymatic modification makes Amikacin a valuable probe for the study of resistance pathways, especially in strains harboring plasmid-borne and chromosomal CEGs [Contrast: Advanced Protocols]. Its use allows for the dissection of multi-drug resistance and the molecular epidemiology of resistant pathogens in both clinical and experimental settings.

Mechanism of Action of Amikacin (BAY416651) Aminoglycoside Antibiotic

Amikacin exerts its antibacterial effect by binding irreversibly to the 16S rRNA of the 30S subunit of bacterial ribosomes. This interaction disrupts the initiation complex, leading to misreading of mRNA and the production of aberrant proteins [See: Reliable Cell-Based Assays]. The molecular structure of Amikacin, specifically its L-hydroxyaminobutyryl amide side chain, imparts resistance to many modifying enzymes, including acetyltransferases, nucleotidyltransferases, and phosphotransferases. However, the AAC (6')-I enzyme can acetylate Amikacin at the 6'-amino position, leading to reduced efficacy in certain strains [Chen et al., 2025]. This mechanism underpins the selective pressure observed in multi-drug resistant organisms.

Evidence & Benchmarks

• In a 2022–2024 multicenter study, 85.19% of carbapenem-resistant Enterobacter cloacae (CREC) isolates were positive for carbapenemase-encoding genes (CEGs), with blaNDM-1 being predominant (Chen et al., 2025, https://doi.org/10.1186/s12866-025-04300-0).
• Amikacin demonstrates resistance to most aminoglycoside-modifying enzymes, except for AAC (6')-I-mediated acetylation, which occurs in a subset of clinical isolates (Chen et al., 2025, https://doi.org/10.1186/s12866-025-04300-0).
• Its water solubility is ≥5.86 mg/mL at ambient temperature; it is insoluble in ethanol and DMSO, which is critical for formulating research-grade stock solutions (APExBIO).
• Amikacin is stable at -20°C as a solid; solutions should be freshly prepared and not stored long-term to avoid degradation (APExBIO).
• Amikacin remains a standard for benchmarking resistance in multi-drug resistant Klebsiella pneumoniae and Enterobacter cloacae models (Semi-Synthetic Aminoglycoside Review).

Applications, Limits & Misconceptions

Amikacin (BAY416651) is widely used in molecular biology and microbiology research to:

• Study the mechanisms of aminoglycoside resistance, especially in carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae.
• Benchmark resistance phenotypes in multi-drug resistant Gram-negative pathogens.
• Evaluate the function of aminoglycoside-modifying enzymes, including AAC (6')-I, in bacterial isolates.
• Develop and validate new diagnostic or screening assays for antibiotic resistance.

However, there are boundaries to its utility:

Common Pitfalls or Misconceptions

• Not effective against strains with high-level AAC (6')-I expression: Amikacin can be inactivated by this enzyme class, so resistance studies must confirm the enzymatic profile of tested isolates [Chen et al., 2025].
• Inappropriate for clinical or diagnostic use: The APExBIO B3431 kit is intended strictly for research applications and is not certified for medical use (APExBIO).
• Stock solution instability: Amikacin solutions should not be stored for extended periods; freshly prepare before use to prevent loss of activity (APExBIO).
• Limited efficacy in non-bacterial systems: It is ineffective in non-prokaryotic (e.g., fungal, viral) models due to ribosomal specificity.

This article extends recent protocol-driven reviews by detailing molecular benchmarks and enzyme-specific resistance pathways not covered elsewhere.

Workflow Integration & Parameters

For optimal experimental reproducibility, the following workflow parameters are recommended:

• Solubility: Dissolve Amikacin in sterile water at ≥5.86 mg/mL. Do not use ethanol or DMSO due to insolubility (APExBIO).
• Storage: Store solid compound at -20°C. Avoid freeze-thaw cycles. Prepare solutions fresh; do not store long-term.
• Preparation: For concentrated stocks, warm at 37°C for 10 minutes or use ultrasonic shaking.
• Shipping: APExBIO ships the B3431 kit on blue ice to preserve compound integrity during transit.
• Compatibility: Amikacin can be used in conjunction with molecular biology assays, HPLC validation (>98% purity), and resistance phenotype screens.

This article clarifies the solubility and handling limits compared to prior scenario-driven guides by providing explicit preparation and stability instructions.

Conclusion & Outlook

Amikacin (BAY416651) remains a cornerstone in antibiotic resistance research due to its structure-driven resistance profile and well-characterized mechanism of action. Its utility is maximized in studies focused on multi-drug resistant Enterobacter cloacae and Klebsiella pneumoniae, particularly for investigating the role of aminoglycoside-modifying enzymes. The robust solubility and stability data, coupled with precise workflow recommendations, ensure reproducibility in laboratory settings. Future resistance monitoring and mechanism-of-action studies will continue to rely on Amikacin as a critical benchmark compound. For full product specifications and ordering, consult the Amikacin (BAY416651) Aminoglycoside Antibiotic product page.

This article updates previous reviews by integrating recent epidemiological findings and enzymatic resistance pathways.